Product Pipeline

Publications

 
 

Publications

Tucatinib (ONT-380)

Progression-Free Survival and Site of First Progression in HER2-Positive Metastatic Breast Cancer Patients With or Without Brain Metastases: A Pooled Analysis of Tucatinib Phase I Studies

European Society for Medical Oncology (ESMO) 2017 Congress. Poster 264

Download Poster » 893KB


Tucatinib, a HER2 Selective Kinase Inhibitor, is Active in Patient Derived Xenograft (PDX) Models of HER2-Amplified Colorectal, Esophageal and Gastric Cancers

European Society for Medical Oncology (ESMO) 2017 Congress. Poster 1639

Download Poster » 428KB


Evaluation of Drug-Drug Interactions (DDI) Between Tucatinib and Capecitabine in Patients With Advanced HER2-Positive Metastatic Breast Cancer from a Phase 1b Study

European Society for Medical Oncology (ESMO) 2017 Congress. Poster 297

Download Poster » 618KB


A Phase 2 Randomized, Double-Blinded, Placebo-Controlled Study of Tucatinib (ONT-380) vs. Placebo in Combination with Capecitabine and Trastuzumab in Patients with Pretreated HER2+ Unresectable Locally Advanced or Metastatic Breast Carcinoma (HER2CLIMB)

American Society of Clinical Oncology Annual Meeting, June 2017. Abstract TPS1107

Download Poster » 413KB


A Phase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib (ONT-380) vs. Placebo in Combination with Capecitabine and Trastuzumab in Patients with Pretreated HER2+ Unresectable Locally Advanced or Metastatic Breast Carcinoma (HER2CLIMB)

San Antonio Breast Cancer Symposium, December 2016. Program OT1-02-09

Download Poster » 417KB


Efficacy Results of a Phase 1b Study of Tucatinib (ONT-380), an Oral HER2-Specific Inhibitor, in Combination With Capecitabine and Trastuzumab in HER2+ Metastatic Breast Cancer, Including Patients with Brain Metastases

San Antonio Breast Cancer Symposium, December 2016. Abstract P4-21-01

Download Poster » 533KB


Cutaneous Responses in HER2+ Metastatic Breast Cancer in Phase 1b Study of Tucatinib (ONT-380), an Oral HER2 Specific Inhibitor in Combination with Capecitabine and/or Trastuzumab in Third Line or Later Treatment

European Society of Medical Oncology (ESMO) 2016 Congress. Poster 278

Download Poster » 720KB


A Phase 2 Randomized, Double-Blinded, Placebo-Controlled Study of Tucatinib (ONT-380) vs. Placebo in Combination with Capecitabine and Trastuzumab in Patients with Pretreated HER2+ Unresectable Locally Advanced or Metastatic Breast Carcinoma

European Society of Medical Oncology (ESMO) 2016 Congress. Poster 312

Download Poster » 116KB


Efficacy results of a phase 1b study of ONT-380, a CNS-penetrant TKI, in combination with T-DM1 in HER2+ metastatic breast cancer (MBC), including patients (pts) with brain metastases.

American Society of Clinical Oncology Annual Meeting, June 2016. Abstract 513

Download Poster » 223KB


A phase 1b study of ONT-380, an oral HER2-specific inhibitor, combined with ado trastuzumab emtansine (T DM1), in HER2+ metastatic breast cancer (MBC)

San Antonio Breast Cancer Symposium, December 2015. Abstract P4-14-20

Download Poster » 207KB


ONT-380 in the treatment of HER2+ breast cancer central nervous system (CNS) metastases (mets)

San Antonio Breast Cancer Symposium, December 2015. Abstract P4-14-20

Download Poster » 1.48MB


A Phase 1b Study of ONT-380, an Oral HER2-Specific Inhibitor, in Combination with Capecitabine (C) and Trastuzumab (T) in 3rd line+ Treatment of HER2+ Metastatic Breast Cancer (MBC)

American Society of Clinical Oncology Annual Meeting, May 2015. Abstract 602

Download Poster » 357KB


ONT-380 in the Treatment of HER2+ Breast Cancer Central Nervous System (CNS) Metastases (Mets)

American Society of Clinical Oncology Annual Meeting, May 2015. Abstract 612

Download Poster » 625KB


A phase 1b study of ONT-380, an oral HER2-specific inhibitor, combined with ado-trastuzumab emtansine (T-DM1), in HER2+ metastatic breast cancer (MBC)

American Society of Clinical Oncology Annual Meeting, June 2014. Abstract TPS662

Download Poster » 310KB


A phase 1b study of ONT-380, an oral HER2-specific inhibitor, combined with ado-trastuzumab (T-DM1), in HER2+ metastatic breast cancer (MBC)

San Antonio Breast Cancer Symposium, December 2014. Poster P5-15-08

Download Poster » 641KB


A phase 1b study of ONT-380, an oral HER2-specific inhibitor, combined with ado-trastuzumab emtansine (T-DM1), in HER2+ metastatic breast cancer (MBC)

American Society of Clinical Oncology Annual Meeting, June 2014. Abstract TPS662

Download Poster » 310KB


A phase 1b study of ONT-380, an oral ONT HER2-specific inhibitor, combined with capecitabine and trastuzumab, in HER2+ metastatic breast cancer (MBC)

American Society of Clinical Oncology Annual Meeting, June 2014. Abstract TPS663

Download Poster » 494KB


ONT-380 (ARRY-380) - An Oral HER2 Inhibitor - Final Phase 1 Results and Conclusions

American Association for Cancer Research Special Conference on Advances in Breast Cancer Research, October, 2013

Download Poster » 1.31MB

Earlier posters regarding ONT-380 (ARRY-380) can be found on Array Biopharma's website »



Checkpoint Kinase 1

Preclinical Pharmacokinetics of CASC-578, a Novel Selective Potent and Orally Bioavailable Small Molecule Checkpoint Kinase 1 Inhibitor

American Association for Cancer Research (AACR) Annual Meeting 2017. Abstract 4090

Download Poster » 431KB


CASC-578, a Novel, Orally Available Checkpoint Kinase 1 Inhibitor, is Active as a Single Agent in Solid Tumors From Diverse Histological Origins and Displays Synergistic Anti-Tumor Activity in Combination With Wee1 Inhibition

American Association for Cancer Research (AACR) Annual Meeting 2017. Abstract 295

Download Poster » 619KB


The Novel Orally Available Sub-Nanomolar Potent and Selective Checkpoint Kinase 1 (Chk-1) Inhibitor CASC-578 is Highly Active in Mantle Cell Lymphoma as a Single Agent and in Combination With Wee-1 Inhibition

American Association for Cancer Research (AACR) Annual Meeting 2017. Abstract 297

Download Poster » 584KB


Discovery and development of orally available sub-nanomolar potent checkpoint kinase 1 inhibitors as potential anti-cancer therapies

American Association for Cancer Research Annual Meeting, April 2016. Abstract #2721.

Download Poster » 804KB



TIGIT

Discovery and Characterization of Novel Antagonistic Antibodies That Bind With High Affinity to Human, Cynomolgus, and Murine TIGIT, an Immune Checkpoint Receptor

American Association for Cancer Research (AACR) Annual Meeting 2017. Abstract 578

Download Poster » 1.13MB